What the GSK, Novartis Deal Means for Biotech
April 23, 2014 at 13:57 PM EDT
The loud welcome given by investors to this week's deal for Novartis and GlaxoSmithKline to trade more than $20 billion of assets could trigger more pacts in the pharmaceuticals sector and beyond.